Search Results
Jan 15, 2026, 05:15 ET LUNGevity and Rising Tide Foundation Issue RFA Tackling Lung Cancer's Toughest Challenges: Drug Resistance and Cancer Recurrence
Recurrence of Lung Cancer, will provide up to $1,000,000 per project over four years, supporting research that has the potential to deliver direct benefits for patients with lung cancer. This work builds on past collaborations, including a research award to improve the early detection of lung cancer."Rising
More news about: LUNGevity Foundation
Jan 15, 2026, 05:00 ET Red Bull gives the M7 World Championship wiiings--marks first partnership with Mobile Legends: Bang Bang's flagship tournament
witness Indonesia transform into a global esports spectacle, enhanced by Red Bull's signature blend of gaming and sporting activations.Ringo Lung, Senior Regional Esports Sales Manager at MOONTON Games, said: "Working with Red Bull is about pushing the boundaries of what gaming and esports
More news about: MOONTON Games
Jan 15, 2026, 04:13 ET LUNGevity Now Accepting Research Grant Applications to Drive Breakthroughs in Lung Cancer
"Since 2002, LUNGevity has funded 200 lung cancer research projects totaling more than $55 million. We are proud to continue our longstanding commitment to lung cancer research as funding for lung cancer studies becomes harder to obtain," said Upal Basu Roy, PhD, MPH,
More news about: LUNGevity Foundation
Jan 14, 2026, 22:02 ET SEASON OF HOPE CONTINUES: NEW JERSEY TEEN PLANS BRIGHT FUTURE AFTER RARE BRAIN TUMOR DIAGNOSIS FOLLOWED BY THE PRECISION OF PROTON THERAPY
opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available,
More news about: ProCure Proton Therapy Center
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
closing stock price on January 9, 2026. The Phase 1 dose-escalation trial of FHD-909 targeting SMARCA4-mutant cancers with a focus on non-small cell lung cancer is advancing as planned, with the trial enrolling patients globally."We are pleased to have raised $50 million in an equity financing,
More news about: Equity Insider
Jan 14, 2026, 08:55 ET NYSE Content Advisory: Pre-Market Update + Inaugural U.S.-Saudi Biotech Alliance Summit Begins in SF
ImmunityBio and NantWorks, will appear on NYSE Live at 9 a.m. ET to discuss ImmunityBio's positive results from its Anktiva clinical program in non-small cell lung cancer.At 9:30 a.m. ET, Black Spade Acquisition III will ring the NYSE opening bell to celebrate its recent IPO. Co-CEOs Dennis Tam, Kester
More news about: New York Stock Exchange
Jan 14, 2026, 05:00 ET New Study Identifies Signature in Blood to Better Predict Type 2 Diabetes Risk
sources for this study include R01HL060712, R01HL170904, R01HL136266, and HHSN268201600034I (contract to the Broad Institute) from the National Heart, Lung and Blood Institute (NHLBI); R01DK126698, R01DK081572, U01DK140761, R01DK134672, R01DK120870, and the New York Regional Center for Diabetes Translation
More news about: Albert Einstein College of Medicine
Jan 13, 2026, 20:18 ET Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
CT-P73 accepted by the U.S. Food and Drug Administration (FDA) in 2025. CT-P70, a novel ADC candidate being developed for the treatment of non-small cell lung cancer (NSCLC), recently received Fast Track designation from the U.S. FDA, enabling expedited interactions throughout the development process and the
More news about: Celltrion
Jan 13, 2026, 16:29 ET In Win for Public Health, Oklahoma Supreme Court Upholds Independence of Tobacco Settlement Endowment Trust
Physicians, Oklahoma Chapter of the American Academy of Pediatrics, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, Americans for Nonsmokers' Rights, and Campaign for Tobacco-Free Kids. The groups were represented by Wyatt McGuire of McGuire Law Firm.
More news about: Campaign for Tobacco-Free Kids
Jan 13, 2026, 08:45 ET Americans Know Little about the Leading Cause of Cancer Death
stroke symptoms, and breast cancer screening, we can — and must — do the same for lung cancer."About the Lung Cancer Action NetworkThe Lung Cancer Action Network (LungCAN) is an association of U.S.‑based lung cancer nonprofit organizations and patient advocacy groups working together to
More news about: Lung Cancer Action Network (LungCAN)
Jan 13, 2026, 08:39 ET Eylsia Nicolas Emerges as One of 2025's Most Remarkable Comebacks as She Enters an Expansive 2026
a major chart during their peak. Nicolas's return to music follows a period in which she was told she might never sing again due to permanent lung and vocal cord damage. Working with medical specialists and sound–engineering teams, she regained her voice through emerging sound–restoration technologies.
More news about: Eylsia Nicolas
Jan 13, 2026, 08:15 ET ACS Annual Statistics Report: Milestone 70 Percent 5-Year Survival Rate for all Cancers Combined; Largest Gains for Advanced and Fatal Cancers
cancer (8% to 18%).Lung cancer will cause the most cancer deaths in 2026, more than second-ranking colorectal cancer and third-ranking pancreatic cancer combined. For the three in four people diagnosed with lung cancer at an advanced stage, five-year survival
More news about: American Cancer Society
Jan 13, 2026, 07:00 ET Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
months before traditional imagingLabcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancerBURLINGTON, N.C., Jan. 13, 2026
More news about: Labcorp
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
events consistent with very low levels of unconjugated payload (such as hematological toxicities and diarrhea), and there were no cases of interstitial lung disease, thus indicating a differentiated safety profile of BHV-1510 from other Trop2 ADCs. The most frequent toxicity was oral mucositis/stomatitis,
More news about: Biohaven Ltd.
Jan 12, 2026, 10:35 ET Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC), with firmonertinib having the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant,
More news about: USA News Group
Jan 12, 2026, 10:10 ET Synchrony Medical Secures Investment from New Jersey Innovation Evergreen Fund (NJIEF) to Scale LibAirty™ Airway Clearance System Nationwide
clearance and improved user comfort compared to conventional airway clearance devices."Synchrony's vision is to fundamentally change how chronic lung disease is treated at home," said Anat Shani, CEO of Synchrony Medical. "With the backing of strong partners like Edge Medical and the NJIEF, we have
More news about: Synchrony Medical
Jan 12, 2026, 10:00 ET Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection
approval expected in the second half of 2026. In addition, the company plans to launch several other blood-based cancer detection tests in 2026, including lung and other indications, run through a common automated laboratory workflow.About FreenomeFreenome is an early cancer detection
More news about: Freenome Holdings, Inc.
Jan 12, 2026, 09:20 ET Lung Cancer Research Foundation and Oncology Advocates United for Climate and Health - International Announce Request for Proposals Now Open for Submission
pollution causes many health hazards, can contribute to the development of lung cancer, and can worsen its prognosis. Increasing evidence indicates that air pollution is a major cause of lung cancer, and the number of estimated lung cancer deaths attributable to air pollution has increased by nearly 30%
More news about: Lung Cancer Research Foundation
Jan 12, 2026, 09:15 ET Lung Cancer Research Foundation Announces 2026 Requests for Proposals
date and maintain momentum in lung cancer discovery.LCRF's primary funding mechanisms are designed to advance its mission of supporting researchers committed to addressing critical challenges in lung cancer by improving early detection, deepening understanding of lung cancer biology, exploring mechanisms
More news about: Lung Cancer Research Foundation
Jan 12, 2026, 09:00 ET Function Launches Integration with Claude, Powered by Anthropic
advanced MRI is designed to detect signs of cancers, unruptured aneurysms, endometriosis, stroke, and more, while the CT scan can search for signals of lung cancer, plaque in the heart, and other serious health conditions. Function is redefining what it means to take control of your health.
More news about: Function Health
Jan 12, 2026, 08:32 ET NYU Langone Health's Perlmutter Cancer Center Announces Upcoming Launch of Molecular Profiling Protocols to Monitor Cancer Treatments
regular molecular testing will become available to all patients being treated at the Perlmutter Cancer Center's Manhattan location for breast cancer and lung cancer, as well as genitourinary and gastrointestinal cancers. These options will eventually be made available to patients being treated for all types
More news about: NYU Langone Health
Jan 12, 2026, 08:30 ET IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
Validation in Lung Cancer and Endometriosis: While a large body of evidence in ProSense®'s treatment of breast cancer continues to accumulate, independent studies demonstrated that IceCure's cryoablation system, combined with radiation therapy, successfully treated non-small cell lung cancer ("NSCLC"),
More news about: IceCure Medical
Jan 12, 2026, 08:10 ET TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts
quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.Forward-Looking Statements This press release contains forward-looking statements. These forward-looking statements
More news about: TransMedics Group, Inc.
Jan 12, 2026, 08:05 ET Rigel Provides Business Update and 2026 Outlook
that over 226,000 adults in the U.S. will be diagnosed with lung cancer in 2025. Lung cancer is the leading cause of cancer death in the U.S, with non-small cell lung cancer (NSCLC) being the most common type accounting for 85-90% of all lung cancer diagnoses.2 RET fusions are implicated in
More news about: Rigel Pharmaceuticals, Inc.
Jan 12, 2026, 08:05 ET PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION
therapies in development for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Pierre Fabre Pharmaceuticals is headquartered
More news about: Pierre Fabre Pharmaceuticals